Pelthos borrows up to $50m for Zelsuvmi rollout and more

14 January 2026

US commercial-stage biopharma Pelthos Therapeutics (NYSE: PTHS) has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance (Nasdaq: HRZN), with $30 million funded at closing and up to $20 million available if certain milestones are met.

The company said the facility is designed to accelerate commercialization of its dermatology-focused portfolio, led by Zelsuvmi (berdazimer) for molluscum contagiosum, and to support planned launches of Xepi (ozenoxacin) and Xeglyze (abametapir), alongside general corporate purposes.

Management framed the deal as a way to keep momentum behind a launch that has already started to show early commercial traction. In its third quarter fiscal 2025 update, Pelthos said Zelsuvmi generated $7.1 million in net revenue, with 2,716 units prescribed by 1,169 unique prescribers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK